Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells

Simon Rauber, Markus Luber, Stefanie Weber, Lisa Maul, Alina Soare, Thomas Wohlfahrt, Neng Yu Lin, Katharina DIetel, Aline Bozec, Martin Herrmann, Mark Kaplan, Benno Weigmann, Mario M. Zaiss, Ursula Fearon, Douglas J. Veale, Juan D. Cañete, Oliver DIstler, Felice Rivellese, Costantino Pitzalis, Markus F. NeurathAndrew N.J. McKenzie, Stefan Wirtz, Georg Schett, Jörg H.W. DIstler, Andreas Ramming

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Inflammatory diseases such as arthritis are chronic conditions that fail to resolve spontaneously. While the cytokine and cellular pathways triggering arthritis are well defined, those responsible for the resolution of inflammation are incompletely characterized. Here we identified interleukin (IL)-9-producing type 2 innate lymphoid cells (ILC2s) as the mediators of a molecular and cellular pathway that orchestrates the resolution of chronic inflammation. In mice, the absence of IL-9 impaired ILC2 proliferation and activation of regulatory T (T reg) cells, and resulted in chronic arthritis with excessive cartilage destruction and bone loss. In contrast, treatment with IL-9 promoted ILC2-dependent T reg activation and effectively induced resolution of inflammation and protection of bone. Patients with rheumatoid arthritis in remission exhibited high numbers of IL-9 + ILC2s in joints and the circulation. Hence, fostering IL-9-mediated ILC2 activation may offer a novel therapeutic approach inducing resolution of inflammation rather than suppression of inflammatory responses.

Original languageEnglish (US)
Pages (from-to)938-944
Number of pages7
JournalNature Medicine
Volume23
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Interleukin-9
Lymphocytes
Inflammation
Arthritis
Chemical activation
Bone
Osteitis
Foster Home Care
Cartilage
Rheumatoid Arthritis
Joints
Cytokines
Bone and Bones
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Rauber, S., Luber, M., Weber, S., Maul, L., Soare, A., Wohlfahrt, T., ... Ramming, A. (2017). Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. Nature Medicine, 23(8), 938-944. https://doi.org/10.1038/nm.4373

Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. / Rauber, Simon; Luber, Markus; Weber, Stefanie; Maul, Lisa; Soare, Alina; Wohlfahrt, Thomas; Lin, Neng Yu; DIetel, Katharina; Bozec, Aline; Herrmann, Martin; Kaplan, Mark; Weigmann, Benno; Zaiss, Mario M.; Fearon, Ursula; Veale, Douglas J.; Cañete, Juan D.; DIstler, Oliver; Rivellese, Felice; Pitzalis, Costantino; Neurath, Markus F.; McKenzie, Andrew N.J.; Wirtz, Stefan; Schett, Georg; DIstler, Jörg H.W.; Ramming, Andreas.

In: Nature Medicine, Vol. 23, No. 8, 01.08.2017, p. 938-944.

Research output: Contribution to journalArticle

Rauber, S, Luber, M, Weber, S, Maul, L, Soare, A, Wohlfahrt, T, Lin, NY, DIetel, K, Bozec, A, Herrmann, M, Kaplan, M, Weigmann, B, Zaiss, MM, Fearon, U, Veale, DJ, Cañete, JD, DIstler, O, Rivellese, F, Pitzalis, C, Neurath, MF, McKenzie, ANJ, Wirtz, S, Schett, G, DIstler, JHW & Ramming, A 2017, 'Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells', Nature Medicine, vol. 23, no. 8, pp. 938-944. https://doi.org/10.1038/nm.4373
Rauber S, Luber M, Weber S, Maul L, Soare A, Wohlfahrt T et al. Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. Nature Medicine. 2017 Aug 1;23(8):938-944. https://doi.org/10.1038/nm.4373
Rauber, Simon ; Luber, Markus ; Weber, Stefanie ; Maul, Lisa ; Soare, Alina ; Wohlfahrt, Thomas ; Lin, Neng Yu ; DIetel, Katharina ; Bozec, Aline ; Herrmann, Martin ; Kaplan, Mark ; Weigmann, Benno ; Zaiss, Mario M. ; Fearon, Ursula ; Veale, Douglas J. ; Cañete, Juan D. ; DIstler, Oliver ; Rivellese, Felice ; Pitzalis, Costantino ; Neurath, Markus F. ; McKenzie, Andrew N.J. ; Wirtz, Stefan ; Schett, Georg ; DIstler, Jörg H.W. ; Ramming, Andreas. / Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. In: Nature Medicine. 2017 ; Vol. 23, No. 8. pp. 938-944.
@article{c3eb4945e2d54bc683eab4e5af487b66,
title = "Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells",
abstract = "Inflammatory diseases such as arthritis are chronic conditions that fail to resolve spontaneously. While the cytokine and cellular pathways triggering arthritis are well defined, those responsible for the resolution of inflammation are incompletely characterized. Here we identified interleukin (IL)-9-producing type 2 innate lymphoid cells (ILC2s) as the mediators of a molecular and cellular pathway that orchestrates the resolution of chronic inflammation. In mice, the absence of IL-9 impaired ILC2 proliferation and activation of regulatory T (T reg) cells, and resulted in chronic arthritis with excessive cartilage destruction and bone loss. In contrast, treatment with IL-9 promoted ILC2-dependent T reg activation and effectively induced resolution of inflammation and protection of bone. Patients with rheumatoid arthritis in remission exhibited high numbers of IL-9 + ILC2s in joints and the circulation. Hence, fostering IL-9-mediated ILC2 activation may offer a novel therapeutic approach inducing resolution of inflammation rather than suppression of inflammatory responses.",
author = "Simon Rauber and Markus Luber and Stefanie Weber and Lisa Maul and Alina Soare and Thomas Wohlfahrt and Lin, {Neng Yu} and Katharina DIetel and Aline Bozec and Martin Herrmann and Mark Kaplan and Benno Weigmann and Zaiss, {Mario M.} and Ursula Fearon and Veale, {Douglas J.} and Ca{\~n}ete, {Juan D.} and Oliver DIstler and Felice Rivellese and Costantino Pitzalis and Neurath, {Markus F.} and McKenzie, {Andrew N.J.} and Stefan Wirtz and Georg Schett and DIstler, {J{\"o}rg H.W.} and Andreas Ramming",
year = "2017",
month = "8",
day = "1",
doi = "10.1038/nm.4373",
language = "English (US)",
volume = "23",
pages = "938--944",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells

AU - Rauber, Simon

AU - Luber, Markus

AU - Weber, Stefanie

AU - Maul, Lisa

AU - Soare, Alina

AU - Wohlfahrt, Thomas

AU - Lin, Neng Yu

AU - DIetel, Katharina

AU - Bozec, Aline

AU - Herrmann, Martin

AU - Kaplan, Mark

AU - Weigmann, Benno

AU - Zaiss, Mario M.

AU - Fearon, Ursula

AU - Veale, Douglas J.

AU - Cañete, Juan D.

AU - DIstler, Oliver

AU - Rivellese, Felice

AU - Pitzalis, Costantino

AU - Neurath, Markus F.

AU - McKenzie, Andrew N.J.

AU - Wirtz, Stefan

AU - Schett, Georg

AU - DIstler, Jörg H.W.

AU - Ramming, Andreas

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Inflammatory diseases such as arthritis are chronic conditions that fail to resolve spontaneously. While the cytokine and cellular pathways triggering arthritis are well defined, those responsible for the resolution of inflammation are incompletely characterized. Here we identified interleukin (IL)-9-producing type 2 innate lymphoid cells (ILC2s) as the mediators of a molecular and cellular pathway that orchestrates the resolution of chronic inflammation. In mice, the absence of IL-9 impaired ILC2 proliferation and activation of regulatory T (T reg) cells, and resulted in chronic arthritis with excessive cartilage destruction and bone loss. In contrast, treatment with IL-9 promoted ILC2-dependent T reg activation and effectively induced resolution of inflammation and protection of bone. Patients with rheumatoid arthritis in remission exhibited high numbers of IL-9 + ILC2s in joints and the circulation. Hence, fostering IL-9-mediated ILC2 activation may offer a novel therapeutic approach inducing resolution of inflammation rather than suppression of inflammatory responses.

AB - Inflammatory diseases such as arthritis are chronic conditions that fail to resolve spontaneously. While the cytokine and cellular pathways triggering arthritis are well defined, those responsible for the resolution of inflammation are incompletely characterized. Here we identified interleukin (IL)-9-producing type 2 innate lymphoid cells (ILC2s) as the mediators of a molecular and cellular pathway that orchestrates the resolution of chronic inflammation. In mice, the absence of IL-9 impaired ILC2 proliferation and activation of regulatory T (T reg) cells, and resulted in chronic arthritis with excessive cartilage destruction and bone loss. In contrast, treatment with IL-9 promoted ILC2-dependent T reg activation and effectively induced resolution of inflammation and protection of bone. Patients with rheumatoid arthritis in remission exhibited high numbers of IL-9 + ILC2s in joints and the circulation. Hence, fostering IL-9-mediated ILC2 activation may offer a novel therapeutic approach inducing resolution of inflammation rather than suppression of inflammatory responses.

UR - http://www.scopus.com/inward/record.url?scp=85027962739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027962739&partnerID=8YFLogxK

U2 - 10.1038/nm.4373

DO - 10.1038/nm.4373

M3 - Article

C2 - 28714991

AN - SCOPUS:85027962739

VL - 23

SP - 938

EP - 944

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 8

ER -